Safeguard Sciences, Inc., founded in 1953 and headquartered in Wayne, Pennsylvania, is a holding company that builds value in growth-stage technology and life sciences businesses in the U.S. and Canada by providing capital, as well as a range of strategic, operational and management resources. The company participates in expansion and early-stage financing transactions, corporate spin-outs, management buyouts, recapitalizations and industry consolidations, typically investing between $5 million and $50 million in portfolio companies. It targets innovative life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices, Regenerative Medicine and Specialty Pharmaceuticals, and technology companies in Internet / New Media, Software as a Service, Financial Services IT and Healthcare IT.

The company’s investment strategy is overseen by a strong group of distinguished board members composed of former and current principals of private and public holding, life sciences and technology companies, as well as equity investment firms. Leveraging the benefits of a public structure to support emerging growth operations, the company can focus on growing their long-term value at an appropriate pace without time-to-exit pressure. Through more than fifty years of service, the company’s expertise and leadership has helped accelerate growth, enable business transformation and build long-term value for its numerous partners, which have become market leaders in their respective sectors and have either been taken public or sold to a strategic buyer. The company’s track record includes participation in the growth and success of such companies as Novell (NASDAQ: NOVL), QVC, Cambridge Technology Partners, Internet Capital Group (NASDAQ: ICGE), CompuCom Systems and Traffic.com.

CURRENT PRICE: $12.06
52-WEEK RANGE: $8.60 - 14.35
AVG DAILY VOLUME (90-DAY): 98,749
FLOAT: 20.2 million
OUTSTANDING SHARES: 20.5 million
MARKET CAPITALIZATION: $247.4 million

INCOME STATEMENT HIGHLIGHTS
REVENUE: Nil
NET INCOME: ($88.4 million)
DILUTED EPS: ($3.99)

All figures for twelve months ended June 30, 2010

BALANCE SHEET HIGHLIGHTS
CASH: $28.2 million
WORKING CAPITAL: $43.4 million
TOTAL ASSETS: $272.6 million
LONG TERM DEBT: $44.3 million
NET WORTH: $185.0 million

All figures as of June 30, 2010

RECENT COMPANY HEADLINE
July 29, 2010 — Safeguard Sciences announced that aggregate revenue of its partner companies for the three months ended June 30, 2010 was $91.6 million, up 47% from $62.3 million for the same partner companies in the same period of 2009. For the six months ended June 30, 2010, the aggregate partner company revenue was $176.9 million, up 45% from $121.8 million for the same partner companies for the same period of 2009. Revenue for Safeguard’s cost and equity method partner companies is reported on a one-quarter lag basis.

SFE PORTFOLIO COMPANIES
Technology: Advantedge Healthcare Solutions, Inc. (39.7%), Authentium, Inc. (20.1%), Beyond.com, Inc. (38.3%), Bridgevine, Inc. (23.4%), MediaMath, Inc. (17.3%), Portico Systems, Inc. (45.4%), Swaptree, Inc. (46.6%)
Life Sciences: Advanced BioHealing, Inc. (28.2%), Alverix, Inc. (49.6%), Avid Radiopharmaceuticals, Inc. (13.5%), Cellumen, Inc. (58.9%), Clariant, Inc. (Nasdaq: CLRT) (27.2%), Garnet BioTherapeutics, Inc. (31.1%), Molecular Biometrics, Inc. (35.1%), NuPath, Inc. (22.9%), Quinova Pharmaceuticals, Inc. (25.7%), Tengion, Inc. (48.3%)

CORPORATE CONTACT INFORMATION
Safeguard Sciences, Inc.
435 Devon Park Drive, Building 800
Wayne, PA 19087
Phone: 610-293-0600 Fax: 610-293-0601
Web Site: www.safeguard.com Email: IR@safeguard.com

The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to its accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. For complete disclaimer information, the reader is hereby referred to the Disclaimer Page of the WallStreet Research Small Cap Conference Book, which this is a part of, or the www.WallStreetResearch.org website.

Copyright © August 2010 Alan Stone & Company LLC All Rights Reserved